In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible\ntreatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics\n(PK) of the compound by intravenous (IV) and oral administrations to rats. Dimethyl sulfoxide\n(DMSO)-based and diazepam injection-based formulations were used to dissolve the compound.\nIn the latter formulation applicable to humans, the changes in PK parameters were monitored at\ntwo different concentrations (1 mg/mL and 2 mg/mL). The area under the plasma concentration-time\ncurve from zero time to infinity (AUCinf) of Ewha-18278 was highest in the DMSO-based formulation\n(2 mg/mL). Also, the concentration was increased 1.6-fold at the low concentration of the diazepam\ninjection-based formulation compared to the high concentration. There was no statistical significance\nin the AUCinf of the compound between DMSO-based formulation (2 mg/mL) and diazepam\ninjection-based formulation (1 mg/mL). These results suggest that Ewha-18278 can be delivered\nto humans by both IV and oral routes. In addition, the diazepam injection-based formulation of\nEwha-18278 appears to be a suitable candidate for dosage development for future toxicity test and\nclinical trial.
Loading....